Company
Arrowhead
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
1
Originals and new uses
Phase 3 trials
11
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Redemplo approved NovelBreakthrough therapyOrphanNov 18, 2025
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute PancreatitisPivotal-lookingRecruiting
Arrowhead PharmaceuticalsIndustry
NCT06880770 · 288 participants (planned) · Start Apr 24, 2025 · Primary completion Mar 2029
Drug: Plozasiran; Placebo · For: Severe Hypertriglyceridemia
Sites: Los Angeles, California; Santa Clarita, California; New Haven, Connecticut · 140 sites in all
- Study of Zodasiran in Adolescent Participants With Homozygous Familial HypercholesterolemiaPivotal-lookingRecruiting
Arrowhead PharmaceuticalsIndustry
NCT07473843 · 10 participants (planned) · Start Oct 2026 · Primary completion Jul 2028
Drug: Zodasiran · For: Homozygous Familial Hypercholesterolemia
Sites: St Louis, Missouri; Viborg, Denmark; Warsaw, Poland
Marketed drugs (1)
Newest FDA action first.
- Redemplo Plozasiran Sodium · 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.